Status of group B streptococcal vaccine development
- Author:
Shun Mei LIN
1
;
Yong ZHI
;
Ki Bum AHN
;
Sangyong LIM
;
Ho Seong SEO
Author Information
- Publication Type:Brief Communication
- Keywords: Vaccines; Group B streptococcus; Streptococcus agalactiae; Conjugate vaccines; Polysaccharides
- MeSH: Aged; Diagnosis; Global Health; Humans; Hygiene; Immunization Programs; Infant; Infant, Newborn; Polysaccharides; Streptococcus; Streptococcus agalactiae; Treatment Outcome; Vaccines; Vaccines, Conjugate; World Health Organization
- From:Clinical and Experimental Vaccine Research 2018;7(1):76-81
- CountryRepublic of Korea
- Language:English
- Abstract: Streptococcus agalactiae (group B streptococcus, GBS) is a leading causal organism of neonatal invasive diseases and severe infections in the elderly. Despite significant advances in the diagnosis and treatment of GBS infections and improvement in personal hygiene standards, this pathogen is still a global health concern. Thus, an effective vaccine against GBS would augment existing strategies to substantially decrease GBS infection. In 2014, World Health Organization convened the first meeting for consultation on GBS vaccine development, focusing on the GBS maternal immunization program, which was aimed at reducing infections in neonates and young infants worldwide. Here, we review the history of GBS infections, the current vaccine candidates, and the current status of immunogenicity assays used to evaluate the clinical efficacy of GBS vaccines.
